Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

Cleveland Clinic research provides further positive validation Nuvectis Pharma's* NXP900 cancer-fighting potential, showing enhanced efficacy when combined with AstraZeneca's blockbuster drug Tagrisso® in EGFR+ lung cancer models. New $18 price target and buy recommendation from Lucid Capital Markets implies 200%+ potential upside as Phase 1b trial approaches

NEW YORK--(BUSINESS WIRE)--Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to decreased cancer cell proliferation and increased apoptosis compared to osimertinib alone.

According to the company, this research from Prof. Ruth Keri’s laboratory at Cleveland Clinic provides critical independent validation of previous findings from AstraZeneca researchers, confirming that NXP900 can effectively combat resistance mechanisms that limit the effectiveness of EGFR inhibitors like Tagrisso, which generates over $5 billion in annual sales.

NXP900, an oral SRC/YES1 kinase inhibitor with a unique mechanism that inhibits both catalytic and scaffolding functions, shows promise in addressing resistance to current standard-of-care treatments. The company is also advancing NXP800, a GCN2 activator in Phase 1b trials for platinum-resistant, ARID1a-mutated ovarian cancer, with encouraging interim data showing partial response and stable disease in several patients.

Industry analysts seem to have taken notice of Nuvectis’s potential. In February 2025, Lucid Capital Markets reportedly initiated coverage with a BUY rating and an $18 price target, projecting peak sales of over $900 million for NXP900 across multiple cancer indications. This represents significant potential upside potential from current levels. With multiple catalysts expected in 2025, including completion of the NXP900 Phase 1a study, initiation of Phase 1b trials, and updated NXP800 clinical data in Q2, Nuvectis seems to be a fascinating company to watch in 2025.

Recent News from Nuvectis

• Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

• Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

• Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

• Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. We are not responsible for the price targets mentioned in this article nor do we it endorse them, they are quoted based on publicly available news reports. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Nuvectis Pharma and was produced as part of their paid subscription to Wall Street Wire. This alert has not been reviewed or approved by Nuvectis Pharma prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.